Summary
A total of 21 patients with advanced metastatic malignant melanoma were treated in this efficacy study of recombinant leukocyte A interferon (interferon alfa-2a). Patients received 18x106 units interferon alfa-2a by i.m. injection daily for the first 10 weeks and then three times weekly for a further 4 months. The symptoms of toxicity observed in this study resembled those previously reported for alfa interferons and included fever, chills, fatigue, anorexia, myalgia, headache, occasional nausea and vomiting, dose-dependent reversible leukopenia, and hepatic transaminase elevations. Of the 21 patients, 12 had evidence of tumor progression, 6 had stable disease for at least 2 months, and complete remission was seen in 3 patients with stage III melanoma. We conclude that interferon alfa-2a appears to have some antiproliferative effect in metastatic malignant melanoma. While its use in stage IV patients with big tumor masses is doubtful, there seems to be therapeutic benefit in earlier stages.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Balch CM, Milton GW (1984) Cutaneous melanoma. Lipponcott, Philadelphia
Beahrs OH, Myers MH (1983) Manual for staging of cancer, American Joint Committee on Cancer. Lippincott, Philadelphia p 117
Creagan ET, Ahmann DL, Green SJ, Long HJ, Rubin J, Schutt AJ, Dziewanowski ZE (1984) Phase II study of recombinant leukocyte A interferon (rIFN-αA) in disseminated malignant melanoma. Cancer 54:2844–49
Creagan ET, Ahmann DL, Frytak St, Long HJ, Chang MN, Itri L (1986) Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: Results in 96 patients. Cancer Treat Rep 70:619–624
Ernstoff MS, Reiss M, Davis CA (1983) Intravenous recombinant alpha-2 interferon in metastatic melanoma. Proc Am Soc Clin Oncol 19:222
Evinger M, Maeda S, Pestka S (1981a) Recombinant leukocyte interferon produced in bacteria has antiproliferative activity. J Biol Chem 256:2113–2114
Evinger M, Rubinstein M, Pestka S (1981b) Antiproliferative and antiviral activities of human leukocyte interferons. Arch Biochem Biophys 210:319–329
Goeddel DV, Yelverton E, Ullrich A, Heyneker HL, Miozzari G, Holmes W, Seeburg PH, Dull T, May L, Stebbing N, Crea R, Maeda S, McCandliss R, Sloma A, Tabor JM, Gross M, Familletti PC, Pestka S (1980) Human leukocyte interferon produced by E. coli is biologically active. Nature 287:411
Gutterman JU, Blumenschein GR, Alexanian R, Yap HY (1980) Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med 93:399–406
Guttermann JU, Fine S, Quesada J (1982) Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance and biologic effects in cancer patients. Ann Int Med 96:549
Herberman RB, Ortaldo JR, Mantovani A, Hobbs DS, Kung HF, Pestka S (1982) Effect of human recombinat interferon on cytotoxic activity of natural killer (NK) cells and monocytes. Cell Immunol 67:160–167
Hersey P, MacDonald M, Hall C, Spurling A, Edwards A, Coates A, McCarthy W (1986) Immunological effects of recombinant interferon alfa-2a in patients with disseminated melanoma. Cancer 57:8, 1666–1674
Horning SJ, Levine JF, Miller RA, Rosenberg SA, Merigan TC (1982) Clinical and immunologic effects on recombinant leukocyte interferon in eight patients with advanced cancer. J Am Med Assoc 247:1718–1772
Itri LM (1987) Incidence and clinical significance of neutralizing antibodies in patients receiving roferon-A (recombinant interferon alfa-2a). Cancer (in press)
Kirkwood JM, Ernstoff MS (1984) Interferons in the treatment of human cancer. J Clin Oncol 2:336–352
Krim M (1980) Towards tumor therapy with interferons. II Interferons: In vivo effects. Blood 55:875
Krown SE, Burk M, Kirkwood JM, Kerr D, Morton DL, Oettgen HF (1984) Human leukocyte (alpha) interferon in metastatic malignant melanoma. American Cancer Society Phase II Trial Cancer. Treat Rep 68:723–726
Mastrangelo MJ, Bellet RE, Berd D (1985) Prognostic factors. In: Clark WH, Goldman LJ, Mastrangelo MJ (eds) Human malignant melanoma. Clinical oncology monographs. Grune and Stratton, New York, pp 273–282
Nagata S, Hideharu T, Hall A, Johnsrud L, Streuli M, Ecsödi J, Boll W, Cantell K, Weissmann C (1980) Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 284:316–320
Quesada JR, Gutterman JU (1983) Clinical studies of recombinant DNA-produced leukocyte interferon (Clone A) in an intermittent schedule in cancer patients. J Natl Cancer Inst 70:1045
Quesada JR, Swanson DA, Trindade A, Gutterman JU (1983) Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Res 43:940–947
Retsas S, Priestman TJ, Newton KA, Westbury G (1983) Evaluation of human lymphoblastoid interferon in advanced malignant melanoma. Cancer 51:273
Robinson WA, Kirkwood J, Harvey H, Mughal T, McCune C, Muggla S, Hawkins M, Muscato M, Pouillart P, Ernstoff MS, Sorell M (1984) Effective use of recombinant human alpha2 interferon (rIFN alpha2) in metastatic malignant melanoma (MMM). Proc ASCO 3:C-234
Rubin BY, Gupta SL (1980) Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents. Proc Natl Acad Sci USA 77:5928
Sherwin SA, Knost JA, Fein S, Abrams PG, Foon KA, Ochs JJ, Schoenberger C, Maluish AE, Oldham RK (1982) A multipledose phase I trial of recombinant leukocyte A interferon in cancer patients. J Am Med Assoc 248:2461
Sherwin SA, Mayer D, Ochs JJ, Abrahams PG, Knost JA, Foon KA, Fein S, Oldham RK (1983) Recombinant leukocyte A interferon in advanced breast cancer. Ann Intern Med 98:598–602
Taylor-Papadimitriou J (1980) Effects of interferons on cell growth and function. In: Gresser J (ed) Interferon. Academic Press, New York, pp 13–42
Thomson DB, McLeod GR (1984) Pilot efficacy study of recombinant leukocyte A interferon (Ro. 22-8181, IFL-alpha-A) in patients with metastatic melanoma. Proc ASCO 3:C-180
Trown PW, Kramer MJ, Dennin RA, Connell EV, Palleroni AV, Quesada J, Gutterman JU (1983) Antibodies to human leukocyte interferon in cancer patients. Lancet I:81–84
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Elsässer-Beile, U., Drees, N., Neumann, H.A. et al. Phase II trial of recombinant leukocyte A interferon in advanced malignant melanoma. J Cancer Res Clin Oncol 113, 273–278 (1987). https://doi.org/10.1007/BF00396385
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00396385